Laplace Interventional, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Laplace Interventional, Inc. - overview
Established
2020
Location
Plymouth, MN, US
Primary Industry
Medical Devices & Equipment
About
Based in the US, founded in 2020 by its CEO, Ramji Iyer, Laplace Interventional, Inc. , operates as a developer and provider of minimally invasive transcatheter treatment for patients suffering from Tricuspid Regurgitation. In March 2025, Laplace Interventional, Inc. raised USD 22 million in series C funding co-led by new investors Aphelion Capital and Unorthodox Ventures, with participation from returning investors Engage Venture Partners, Alpha JWC Ventures and Features Capital.
The company offers a prosthetic transcatheter valve that is used for the treatment of tricuspid regurgitation. The company uses transcatheter tricuspid valve technology to increase the life expectancy of patients suffering from tricuspid regurgitation (TR). The company will use the March 2025 funding for further growth and development.
Current Investors
Mayo Clinic Ventures, ShangBay Capital, Alpha JWC Ventures
Primary Industry
Medical Devices & Equipment
Sub Industries
Monitoring Equipment
Website
www.laplaceint.com
Verticals
HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.